Loading
A Yonsei oncologist who has led checkpoint-inhibitor and combination trials in lung and head-and-neck cancer.
Hye Ryun Kim is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, working in thoracic and head and neck oncology. She has led checkpoint-inhibitor and combination trials in lung cancer and head and neck cancer, including trials of PD-1 combinations in non-small-cell lung cancer and head and neck squamous cell carcinoma. Her work also includes immunotherapy biomarker studies that seek to identify which patients respond to immune checkpoint inhibitors. Her interests are lung cancer, head and neck cancer and immunotherapy.
| Title | Journal | Year |
|---|---|---|
| Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 | Journal of Clinical Oncology | 2021 |
| Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | Journal of Clinical Oncology | 2013 |
| PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients | Scientific Reports | 2016 |
Shares Severance Hospital, Yonsei University, Non-small-cell lung cancer.
Shares Severance Hospital, Yonsei University, Non-small-cell lung cancer.
Shares Severance Hospital, Yonsei University, Head and neck squamous cell carcinoma.
Shares Severance Hospital, Yonsei University, Non-small-cell lung cancer.